Medincell Resumes Trading After Suspension Amid Pending Announcement
Event summary
- Trading in Medincell shares on Euronext Paris was suspended at 9:00 a.m. CEST on October 9, 2026, at the company's request.
- Trading resumed at 2:45 p.m. CEST the same day, following the pending publication of a press release.
- Medincell's BEPO® technology is licensed to Teva as SteadyTeq™, with two FDA-approved treatments (UZEDY® and WELTRUZA™) marketed by Teva.
- Olanzapine LAI received FDA approval in October 2026, with a U.S. launch planned in Q4 2026 and a European MAA accepted by EMA in May 2026.
The big picture
Medincell's resumption of trading follows a brief suspension, highlighting the strategic importance of its BEPO® technology in the biopharmaceutical sector. The company's focus on long-acting injectables aligns with industry trends toward improved patient adherence and reduced environmental impact. With Teva as a key partner, Medincell is positioned to capitalize on regulatory milestones and commercial launches, though execution risks remain.
What we're watching
- Regulatory Momentum
- The pace at which Medincell secures additional regulatory approvals for its pipeline, particularly in Europe, will determine its commercial expansion.
- Commercial Execution
- Whether Teva can effectively launch and market WELTRUZA™ in the U.S. and Europe, given its existing partnership with Medincell.
- Market Reaction
- How investors interpret the resumption of trading and any forthcoming announcements, particularly in light of the company's strategic positioning in long-acting injectables.
Related topics
